Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 0.1× sales vs its 12.5× historical median P/S.
Fair value ≈ $15.87 · price $0.18 today
Undervalued · 99% below
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$AFMD $CTM FACTS: Recent Pipeline Expansion: Separate from the backlog, CTM's qualified opportunity pipeline stands at $938 million. CTM additionally entered a new $250 million Multiple Award Contract (MAC) with the U.S. Navy, which will build future backlog through individual task orders. DO YOUR RESEARCH. WITH A BLINK IT SOON WILL BE $25 when its widely known...
$AFMD Death.. lets see if there's any connection to these in the ARTV offering, and Gilde?
-The offering included participation from Caligan Partners, Venrock Healthcare Capital Partners, Adage Capital Partners, RA Capital Management, Viking Global Management, Samsara BioCapital, EcoR1 Capital, Blackstone Multi-Asset Investing, GC Corporation, GC Cell, RTW Investments, Blue Owl Healthcare Opportunities and a Large Mutual Fund.
$AFMD Still believe Gilde involved. Still believe they bought millions @ .23ish to average down. Artiva B.O. @ $5-$7. I.C.E. IP offers near certain FCF of $550 M/yr with RMAT.. on AFM-13 alone!
@Think_Bigly can't believe $ARTV is trading around 10! Thought about buying some earlier this year but the pain from $AFMD is too deep to justify any investment into the biotech sector.
$AFMD Artiva prices $300M underwritten common stock and pre-funded warrant offering at $11.52 after positive AlloNK autoimmune data and FDA alignment on single Phase 3 trial
$AFMD Still the most credible analysis:
- Recapitalization (60%): Highest likelihood—fits distressed restructurings where existing stakeholders inject funds to stabilize and advance acimtamig toward Phase 3. RMAT reduces regulatory risk, making it fundable (~50-70% success rate for RMAT therapies reaching approval). Pre-insolvency cash was ~€10M (Q3 2024), so a €20-50M round could extend runway to 2027 data readouts.
-Buyout (30%): Reasonable for a full acquisition, especially if a suitor values the IP/pipeline at $100-200M EV (based on RMAT precedents; e.g., similar IO assets traded at 2-3x peak cash in 2024 deals). No direct rumors, but 2024's 1,078 biotech M&As show appetite for late-stage oncology.
